Winton Group
ARTV icon

Winton Group’s Artiva Biotherapeutics ARTV Stock Holding History

Winton Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$212K Buy
+29,804
New +$301K 0.01% 934

Other funds holding ARTV

Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Winton Group's ARTV Position: Q3 2026 in Review

Winton Group opened a new position in Artiva Biotherapeutics (ARTV) in Q3 2026: 29,804 shares worth $212K. The stake represents 0.01% of the portfolio and ranks #934 among its holdings.

50 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

  • Winton Group held 29,804 shares of Artiva Biotherapeutics worth $212K as of Q3 2026.
  • Artiva Biotherapeutics was a new Winton Group position in Q3 2026.
  • Artiva Biotherapeutics made up 0.01% of Winton Group's portfolio in Q3 2026, its #934 holding.
  • 50 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Winton Group's 13F filing for Q3 2026, filed 12 Nov 2026.